Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine

• DOI: 10.5387/fms.2021-28
• Publication Date: 2022-02-24T22:10:07Z
• Authors: Yurie Kobashi; Yuzo Shimazu; Takeshi Kawamura; Yoshitaka Nishikawa; Fumiya Omata; Yudai Kaneko; Tatsuhiko Kodama; Masaharu Tsubokura
• Keywords: spike protein; Antibody titer

This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during participants' work days for six weeks thereafter. Antibody titers peaked 6-13 after second (days 27-34 first), followed by steady decrease. Six males had significantly lower peak antibody than females (p = 0.016 t-test); older (median age 53 years) younger 35 but without statistical significance value=0.24 t-test).